Specific Anti-IIa Activity is a Key Indicator of Safety and Efficacy in Validation of Biosimilarity of Unfractioned Heparin Preparations
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605538190 | ||
| 003 | CHVBK | ||
| 005 | 20210128100901.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10517-015-2782-3 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10517-015-2782-3 | ||
| 245 | 0 | 0 | |a Specific Anti-IIa Activity is a Key Indicator of Safety and Efficacy in Validation of Biosimilarity of Unfractioned Heparin Preparations |h [Elektronische Daten] |c [A. Mironov, D. Goryachev, E. Garvishina, R. Niyazov, O. Ivanova] |
| 520 | 3 | |a We compared anti-IIa activity of a heparin analogue and a reference product was carried out to confirm their biosimilarity. The experiment was based on the method of estimation of anti-IIa activity of a commercial sodium heparin preparation according to United States Pharmacopoeia. High similarity of the two medicinal heparin preparations by this parameter is shown. The method is recommended for the use in comparability studies. | |
| 540 | |a Springer Science+Business Media New York, 2015 | ||
| 690 | 7 | |a unfractioned heparin |2 nationallicence | |
| 690 | 7 | |a quantitave estimation of activity |2 nationallicence | |
| 690 | 7 | |a anti-IIa activity |2 nationallicence | |
| 700 | 1 | |a Mironov |D A. |u Research Center for Evaluation of Medical Products, the Ministry of Health of the Russian Federation, Moscow, Russia |4 aut | |
| 700 | 1 | |a Goryachev |D D. |u Research Center for Evaluation of Medical Products, the Ministry of Health of the Russian Federation, Moscow, Russia |4 aut | |
| 700 | 1 | |a Garvishina |D E. |u Research Center for Evaluation of Medical Products, the Ministry of Health of the Russian Federation, Moscow, Russia |4 aut | |
| 700 | 1 | |a Niyazov |D R. |u Research Center for Evaluation of Medical Products, the Ministry of Health of the Russian Federation, Moscow, Russia |4 aut | |
| 700 | 1 | |a Ivanova |D O. |u Research Center for Evaluation of Medical Products, the Ministry of Health of the Russian Federation, Moscow, Russia |4 aut | |
| 773 | 0 | |t Bulletin of Experimental Biology and Medicine |d Springer US; http://www.springer-ny.com |g 158/4(2015-02-01), 450-452 |x 0007-4888 |q 158:4<450 |1 2015 |2 158 |o 10517 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10517-015-2782-3 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10517-015-2782-3 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Mironov |D A. |u Research Center for Evaluation of Medical Products, the Ministry of Health of the Russian Federation, Moscow, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Goryachev |D D. |u Research Center for Evaluation of Medical Products, the Ministry of Health of the Russian Federation, Moscow, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Garvishina |D E. |u Research Center for Evaluation of Medical Products, the Ministry of Health of the Russian Federation, Moscow, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Niyazov |D R. |u Research Center for Evaluation of Medical Products, the Ministry of Health of the Russian Federation, Moscow, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ivanova |D O. |u Research Center for Evaluation of Medical Products, the Ministry of Health of the Russian Federation, Moscow, Russia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Bulletin of Experimental Biology and Medicine |d Springer US; http://www.springer-ny.com |g 158/4(2015-02-01), 450-452 |x 0007-4888 |q 158:4<450 |1 2015 |2 158 |o 10517 | ||